ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc., a Contract, Testing, Development and Manufacturing Organization (CTDMO), have announced a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program.   ViGeneron’s lead product VG901 targets a disease gene for Retinitis pigmentosa (RP), for which there is currently no approved treatment option. VG901 is developed from ViGeneron’s proprietary next gener...